The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Aberdeenman- Fair point. I didn't look at it that way (deal before ceo) . But makes sense either way. Let's see what happens.
Scaryone-I would also expect the Ceo news first, as that seems the logical step. I wouldn't like to second CB and NFX however ??
All valid points Ganners.
Happens to all of us Thompi. Timing the markets can never be perfected (I don't think) I have topped up and seen price drop too many times now on many shares. Generally one rule I try and follow is not to take action on the bell and in the first hour. This does mean missing out some crazy/amazing day risers, but does help bring some discipline. Anyway, hopefully we will atleast do 1 bag from here, so you should be OK. GL
Agree Sailor. Having multiple players in any given market is not a bad bad thing. It shows that there is demand/need for the product. I am/was hoping that NFX take some kind of first mover advantage in this area, bit like Novacyt did in early this year, as that would take this company to new levels. Anyway, lets see what they are working on. Should find out soon enough. Bit of speculation on my side, but I guess the order will be:
1. Notification of appointment of New CEO and other NEDs
2. Any other business updates - not any specific order:
- Covid related programme
- IPF/NXP2 deal related update/progress
- NXP1 progress with Ox
- NPX4 updates
- Other joint programme updates
Evening, I was reading about this, thought I would share here. Do people see this as a competitor to NFX - NXP2? If so, how does it impact NFX? Link:
https://endpts.com/galecto-reaps-64m-to-bring-lead-drug-across-ipf-finish-line-while-making-moves-in-nash-and-beyond/
On a side note: Lots of battle of egos on this board. I was hoping people would provide more constructive notes (both for and against) the investment case in the company, rather than attempting to get one over the other person.
@ Soup - Agreed!
@Earl - Maybe, read this for starters! - https://nuformix.com/app/uploads/2018/12/NFX-NXP002-IPF-Results-RNS-FINAL.pdf
As i suggested yesterday, its better to be cautious rather than get over excited. I think it would be best to stop guessing as to when the news will land and what the news will be. We can speculate based on the information available to us, but that's all it is. No one knows. I am taking all these messages about rumours and leaks with a pinch of salt, because over the last 6/9 months we know how CB has operated. Nothing gets out and the official statements/ RNS notifications which have landed have surprised/have been unexpected to most of the LT holders.
Also cautious of the recent pump, because I noticed a lot of activity on social media, by known rampers. We know their modus operandi. They buy, go on a ramp, rinse and repeat old/published news, mis-represent certain information by not posting the full context, draw up ridiculous mcap and sp targets to lure PIs in and then sell for 10/15%.
Morning All,
Good to see some volume finally and the SP heading back up in the right direction. I am hoping that we are close some positive updates (which we are expecting). However, I am still cautious and not overly excited until we see further news from the company itself.
Also cautious because some of the twitter handles (not all) who are tagging #NFX are known PND crews. I hope I am wrong, and that there is genuine interest building and developing in this company.
Cheers
Morning all,
Found this article. NINTEDANIB is currently one of the two available treatments for IPF. These are capsules, but we potentially have a inhaled product. Let's hope we are not too far away with some positive news for us all.
https://www.google.com/amp/s/www.expresspharma.in/amp/covid19-updates/glenmark-launches-nindanib-nintedanib-for-pulmonary-fibrosis-in-india/
Evening all,
Found an interesting research document which looks to be recent, thought I would share here. Cheers
https://www.google.com/url?sa=t&source=web&rct=j&url=https://www.europeanreview.org/wp/wp-content/uploads/9169-9171.pdf&ved=2ahUKEwj71oyEvqjsAhUuaRUIHaVMCJsQFjABegQICRAH&usg=AOvVaw1fKMmF788gR4mDr0MkHFot
Hi all, NFX holder here, (have been holding for a while - needless to say frustrated with slow/little progress made this year - this is relative to other small pharmas who have done very well off course). I can sense that here too from fellow holders!
Just a a few points/questions from me:
1. 22 July 2020: "During the year, we prioritised development of our anti-fibrotic candidate, NXP002, and are
developing an inhaled formulation" - This hasn't been explicitly mentioned in the latest update, so wonder if this still being progressed? (My guess is that it is as, this could be USP for 002 and perhaps 004.
2. 27th May 2020: This update mentioned a "fall-out" between NSB and parent company, stalling the milestone payment due to NFX. Would it fair to say this may been written off? Is anyone aware of the status of that partnership?
3. NXP002 - Between May update and July update, there seems to have been a change in the approach to take this forward (or so it would seem)? From:
- May - Out licensing progressing - "out-licensing of pan-Asian rights to the Company’s NXP002 programme are progressing well, albeit at a slower pace"
- June - Resignation of DG
- July - Evaluation of Inhaled product/ Covid link- "we prioritised development of our anti-fibrotic candidate, NXP002, and are developing an inhaled formulation. Our preparations for first clinical exposure areunderway. We are looking at all options for deriving value from this product globally"
- October - Further Evaluation "seek global licensing partners in addition to continued negotiations on licensing for the Asian market" + "Certain Group assets to be evaluated for treating the effects of Covid-19" + "evaluation of the benefits of NXP002 in combination with existing marketed products"
- So it looks like we went from - close to landing an out-licensing deal earlier in Q1/Q2, back to re-evalauting the product, re-negotiating, exploring other markets/options right now. I wonder if this change in approach/"strategy" is because DG left or did DG leave because his vision wasn't in line with this approach?
4. From an investment perspective, its still a hold (I think!) :) mainly due to the product potential and current market conditions- lets see how Q4 plays out. Criteria:
- Product - Excellent - Potentially world class, especially 002
- Market Conditions - Excellent- In the current climate, there is/would be serious demand for this type of drug
- Finance Structure / Cash Burn - Average/Ok - Two placings in less than 12 months. not great
- Management - Poor - Many changes in Board, significant milestones not met - YET!
GLA
Hi Gunner, New to LSE, but have been in TSI for a while. I was also looking at the Weshop LinkedIn pages but there doesn't seem to be much updates on there either. Anyway, I am more excited about Brandshield and the potential ipo. GLA